Spartan Bioscience, a US-based company develoing technology for on-demand DNA testing, has obtained an undisclosed amount of funding from imaging equipment maker Canon.
Canon invested through its recently established subsidiary Canon BioMedical, which aims to produce technologies and services for the biomedical research and healthcare sectors.
The funding was provided as part of a strategic partnership to work with Spartan on future diagnostic technologies such as rapid genetic testing. Spartan previously secured approximately $280,000 across three rounds from 2009 to 2012, according to regulatory filings.
Seymour Liebman, executive vice-president, chief administrative officer and general counsel of Canon, and a member of Canon BioMedical’s board of directors, will join Spartan’s board.
Liebman said: “Canon is excited to work with Spartan Bioscience on developing breakthrough technologies in the area of genetic testing. Spartan’s goals align with our mission to provide enhanced diagnostic testing systems that can help improve human health worldwide.”